Researchers at the Australian National University (ANU) have discovered a gene mutation that causes psoriasis, a skin disease characterized by itchy, scaly patches commonly found on the knees, elbows, trunk, and scalp.
The mutation of the IKBKB gene is responsible for causing psoriasis, as revealed in a paper published in the journal Nature Communications.
Individuals with two copies of this gene mutation may develop psoriatic arthritis, a joint swelling condition associated with psoriasis.
Psoriasis affects approximately 7.5 million to 8 million people in the United States and 125 million individuals globally.
In Australia, around 2.3 to 6.6 percent of the population is impacted by this immune-related inflammatory condition.
Chelisa Cardinez, a postdoctoral scientist at ANU John Curtin School of Medical Research and lead author of the study, explained that the mutation was identified using a mouse model.
While there is currently no cure for psoriasis, various treatment options such as ointments, oral therapy, and injections are available.
Ms. Cardinez expressed optimism that the research on the IKBKB gene could pave the way for a potential cure for psoriasis in the future.
“By developing a better understanding of the IKBKB gene and its role in disease onset, we could move closer to finding a cure, offering hope to thousands of Australians,” she stated.
Early detection of psoriatic arthritis was also emphasized as crucial for better health outcomes.
Two New Psoriasis Treatments Placed on PBS
Two new psoriasis treatments were listed on the Australian government’s Pharmaceutical Benefits Scheme (PBS) scheme on 1 Oct. 2023.
Associate Professor Peter Foley from St Vincent’s Hospital Melbourne described the listing of these treatments as a significant milestone in addressing the clinical needs of patients with severe chronic plaque psoriasis.
“The reimbursement of this first-in-class therapy option for Australians living with severe chronic plaque psoriasis represents a major milestone in helping to address the substantial, unmet, clinical need for these patients,” he mentioned.
Dr. Foley highlighted the importance of long-term treatment for patients with plaque psoriasis to maintain symptom control and prevent relapses.
